2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
12/07/16Ionis Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
CARLSBAD, Calif., Dec. 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14 in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website.  The replay will be available within 48 hours and will be archived for... 
 
11/15/16Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
Significant reductions in ANGPTL3, triglycerides and LDL cholesterol observed Interim data presented during the Late Breaker Session at the American Heart Association Meeting CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive results from an interim analysis of a Phase 1/2a study of IONIS-ANGPTL3-LRx. In this study, subjects with elevated triglycerides achieved subst... 
 
11/09/16Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
Conference Call Webcast Wednesday, November 9, 9:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Nov. 9, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported income from operations of $16.1 million and a loss from operations of $87.5 million for the three and nine months ended September 30, 2016, respectively.  The Company also reported pro forma operating income of $33.7 million and a pro forma net operating loss (NOL) of $30.5 million, both excluding non-cash s... 
 
11/07/16Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
- Second Positive Phase 3 Study Provides Further Evidence of SPINRAZA's Efficacy and Favorable Safety Profile - - Results Were Statistically Significant and Clinically Meaningful - CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 7, 2016-- Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of CHERISH, th... 
Download PDF
11/02/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 2, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 in New York, NY 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 in New York, NY The above listed dates are subject to change. Details on presentation times or... 
 
11/01/16Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
-- Statistically significant, dose-dependent reductions in Factor XI activity observed -- CARLSBAD, Calif., Nov. 1, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In this Phase 2 study patients treated with IONIS-FXIRx achieved statistically significant, dose-dependent reductions in Factor XI activity. There were no clini... 
 
10/28/16Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Nusinersen Granted Priority Review by FDA EMA Plans to Follow Accelerated Assessment Timeline CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 28, 2016-- Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review, and that the company's Marketing Authorization Application (MAA) has been validated by the European Medicines... 
 
10/26/16Webcast Alert: Ionis Pharmaceuticals' Third Quarter 2016 Financial Results Conference Call
- Webcast scheduled for Wednesday, November 9 at 9:30 a.m. Eastern Time CARLSBAD, Calif., Oct. 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 9 at 9:30 a.m. Eastern Time to discuss its third quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com.  A webcast replay ... 
 
10/08/16New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
- Initial Phase 3 Safety Data Presented in Infantile-onset Spinal Muscular Atrophy Demonstrated Favorable Safety Profile with no Treatment Related Adverse Events - - Analysis of Ongoing Phase 2 Open-label Study Demonstrated Beneficial Effect in Infants Prior to Onset of Symptoms –CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--New data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented ... 
 
09/28/16Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
CARLSBAD, Calif., Sept. 28, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the Lifetime Achievement Award from the Oligonucleotide Therapeutics Society, OTS. The OTS Lifetime Achievement Award recognizes Dr. Crooke's lasting commitment to the field of oligonucleotide therapeutics through outstanding contributions to education, ... 
 
09/26/16Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Submission of Marketing Authorization Application to the European Medicines Agency Planned in the Coming Weeks CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Ionis (NASDAQ:IONS) today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen, an investigational treatment for spinal muscular atrophy ... 
Download PDF
09/22/16Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
CAMBRIDGE, Mass., Sept. 22, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in The Lancet of key clinical results of two randomized, controlled studies of IONIS-APO(a)Rx and IONIS-APO(a)-LRx, the company's Lp(a)-lowering drugs designed to treat cardiovascular disease and aortic valve stenosis.  Lipoprotein(a), or Lp(a), is an independent, causal, genetic risk factor for cardiovascular disease and ao... 
 
09/15/16Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome
--Largest study conducted to date involving people living with FCS-- --Findings to be presented during American Society for Preventative Cardiology Congress-- CAMBRIDGE, Mass. , Sept. 15, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced ... 
 
08/31/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Aug. 31, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 in Boston, MA 2016 Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York, NY The above listed dates are subject to change.  Details on presentation ti... 
 
08/22/16Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society
CARLSBAD, Calif., Aug. 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the E. B. Hershberg Award for important discoveries in medicinally active substances by the American Chemical Society, a society representing more than 150,000 scientists.  The E. B. Hershberg Award recognizes Dr. Crooke's achievements in leading the crea... 
 
08/09/16Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Conference Call Webcast Tuesday, August 9, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 9, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its financial results for the first half of 2016 were in line with the Company's expectations and the Company is on track to meet its pro forma NOL and cash guidance for the year. "The recent announcement to file for regulatory approval of nusinersen based on positive results from an interim analysis ... 
 
08/01/16Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
— Biogen Intends to File Marketing Applications for Nusinersen with Regulatory Authorities in the Coming Months — — Biogen Exercises Option to Develop and Commercialize Nusinersen Globally — — Companies to Host Webcast Today at 9:00 a.m. EDT to Provide Program Update — CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 1, 2016-- Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy (... 
 
07/28/16Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)
CAMBRIDGE, Mass., July 28, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy (FPL).  FPL is a rare lipid disorder characterized by abnormal fat distribution across the body and a range of metabolic abnormalities, including severe type 2 diabetes, high triglycerides, and accu... 
 
07/26/16Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
- Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif., July 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, August 9 at 11:30 a.m. Eastern Time to discuss its second quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will b... 
 
07/19/16Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
CARLSBAD, Calif., July 19, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned $10 million from Janssen Biotech, Inc. (Janssen) upon licensing IONIS-JBI1-2.5Rx, an orally delivered antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease.  Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5Rx once Ionis... 
 
07/12/16Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
-Innovative New Mechanism Allows Antisense Drugs to Increase the Production of Specific Proteins By Up to 150%- CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication of new research findings in Nature Biotechnology describing a new mechanism of action for antisense technology, which further expands the potential reach of antisense technology.  The paper entitled "Translation efficiency of mRNAs is increased by antisense olig... 
 
07/07/16Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Evidence for disease stabilization observed in patients with TTR amyloid cardiomyopathy Substantial reductions in both mutant and wild-type TTR protein observed in patients with familial amyloid polyneuropathy CARLSBAD, Calif., July 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONIS) announced today positive results from two ongoing trials with IONIS-TTRRx: An ongoing investigator-sponsored, open-label Phase 2 study in patients with TTR amyloid cardiomyopathy, w... 
 
06/29/16Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome
People affected by FCS invited to share their experience CAMBRIDGE, Mass., June 29, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the launch of the first-ever research study to understand the multi-dimensional impact of familial chylomicronemia syndrome (FCS) from the perspective of... 
 
06/27/16Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes
CAMBRIDGE, Mass., June 27, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned  subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication in Diabetes Care of positive clinical data from a Phase 2 study of volanesorsen in patients with high plasma triglyceride (TG) levels and type 2 diabetes.  Results from the study showed that, in addition to reductions in plasma TG and apolipoprotein C-III (ApoC-III), a key factor in TG regulation, volanesorsen improved insuli... 
 
06/22/16Ionis Pharmaceuticals to Host R&D Day
- Webcast on Wednesday, July 13 at 8:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., June 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will host an R&D Day on Wednesday, July 13 at 8:00 a.m. Eastern Time at The London NYC in New York, NY. The agenda for the meeting is as follows: 8:00 a.m. – 8:30 a.m. ET – Breakfast 8:30 a.m. – 12:30 p.m. ET – Presentations 12:30 p.m. – 1:00 p.m. ET – Networking luncheon In addi... 
 
05/26/16Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Conference call scheduled for 9 am Eastern Time today CARLSBAD, Calif., May 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program.  Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy.  Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardi... 
 
05/23/16Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
CARLSBAD, Calif. and HOUSTON, May 23, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and The University of Texas MD Anderson Cancer Center today announced the formation of a strategic alliance to discover and develop novel cancer therapeutics. Combining advances made with Ionis' antisense technology, which provides enhanced potency for effectively engaging targets in solid and liquid tumors, with MD Anderson's expertise will allow Ionis and MD Anderson to develop novel therapeut... 
 
05/16/16Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Study designed to support regulatory filings in U.S., E.U. and Canada for volanesorsen CAMBRIDGE, Mass., May 16, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing innovative treatments for serious cardiometabolic diseases, today announced the completion of enrollment in the COMPASS study, a randomized, double-blind, placebo-controlled, Phase 3 study of volanesorsen in patients with severe hypertriglyce... 
 
05/05/16Ionis Pharmaceuticals Provides Corporate Update at 2016 Annual Meeting of Stockholders
- Conference Call Webcast on Friday, June 3 at 5:10 p.m. ET at www.ionispharma.com CARLSBAD, Calif., May 5, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will present a general corporate update in conjunction with its 2016 Annual Meeting of Stockholders and Open House on Friday, June 3 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. PT – Annual Meetin... 
Download PDF
05/04/16Ionis Reports Financial Results and Highlights for First Quarter 2016
CARLSBAD, Calif., May 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter were in line with the company's expectations. "2016 is off to a strong start. Target enrollment is complete in four Phase 3 studies across nusinersen, IONIS-TTRRx and volanesorsen. These important new drugs are now one step closer to potentially reaching the market and being available to patients. We are actively engaged in NDA preparation... 
Download PDF
05/03/16Ionis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO®
CARLSBAD, Calif. and CHICAGO, May 3, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Kastle Therapeutics, LLC today announced that Kastle has acquired global rights to develop and commercialize KYNAMRO (mipomersen sodium) injection. KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprote... 
Download PDF
04/22/16Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
- Webcast scheduled for Wednesday, May 4 at 10:30 a.m. Eastern Time CARLSBAD, Calif., April 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 4 at 10:30 a.m. Eastern Time to discuss its first quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be ... 
Download PDF
04/20/16Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Webcast scheduled for Thursday, April 21 at 11:00 a.m. PDT/ 2:00 p.m. EDT CARLSBAD, Calif., April 20, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on its ongoing open-label Phase 2 clinical study of nusinersen in infants with spinal muscular atrophy (SMA) at the American Academy of Neurology (AAN) meeting in Vancouver, BC.  The data reported today show that there have been no new events, as defined by progression to permanent ventilation or death, i... 
Download PDF
04/15/16Ionis Pharmaceuticals Highlights Antisense Drugs to Treat Neurological Diseases at the AAN Meeting
Ionis and its collaborators to present more than 12 presentations and posters on Ionis' neurological disease programs Webcast to provide update on nusinersen Phase 2 open-label study in infants with SMA and to review Ionis' other neurological disease programs scheduled for Thursday, April 21 at 2:00 p.m. EDT CARLSBAD, Calif., April 15, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Ionis and its collaborators will present a dozen presentations and post... 
Download PDF
04/07/16Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
CARLSBAD, Calif., April 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program. IONIS-TTRRx is currently being evaluated by IONIS in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. A Phase 3 study, CARDIO-TTR, is also being planned by GSK to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy.  GSK is in the process of finalizing the protocol for the CARDI... 
Download PDF
04/06/16Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 6, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the 15th Annual Needham Healthcare Conference at 4:40 p.m. ET on Tuesday, April 12, 2016 in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis... 
Download PDF
04/01/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., April 1, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 in New York, NY; 41st Annual Deutsche Bank Health Care Conference on Thursday, May 5, 2016 in Boston, MA; and Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, ... 
Download PDF
03/31/16Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA
Ionis Earns $7.5M Milestone Payment from Biogen CARLSBAD, Calif., March 31, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $7.5 million from Biogen for advancing nusinersen in the open-label extension study, SHINE. The SHINE study was initiated in October 2015 to provide nusinersen to infants and children with spinal muscular atrophy (SMA) who have completed their participation in the Phase 3 ENDEAR and CHERISH studies... 
Download PDF
03/31/16Akcea Therapeutics Supports World Lipodystrophy Day
CAMBRIDGE, Mass., March 31, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, recognizes World Lipodystrophy Day and has partnered with Lipodystrophy United (lipodystrophyunited.org) to raise awareness of those living with lipodystrophy. "We are proud to join forces with the patient community in celebration of World Lipodystrophy Day. We stand in support... 
Download PDF
03/22/16Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case
CARLSBAD, Calif., March 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a jury in the United States District Court, Northern District of California found in favor of Merck and Ionis in a patent dispute related to Gilead's sofosbuvir-based medicines for the treatment of hepatitis C virus (HCV), including Sovaldi and Harvoni.  The jury found in favor of Merck and Ionis upholding all claims from the two patents in the case, including two methods an... 
Download PDF
03/04/16Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the Cowen and Company 36th Annual Health Care Conference at 2:30 p.m. ET on Tuesday, March 8, 2016 in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section of t... 
Download PDF
02/29/16Ionis Pharmaceuticals Supports Rare Disease Day
CARLSBAD, Calif., Feb. 29, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) recognizes International Rare Disease Day and has partnered with the Amyloidosis Research Consortium (arci.org), Cure SMA (curesma.org), and Myotonic Dystrophy Foundation (MDF.org) to raise awareness of those living with rare diseases. As part of Ionis' initiative to recognize the value of bringing together researchers, patients, caregivers and advocacy groups, Ionis will be hosting a seminar for its emplo... 
Download PDF
02/25/16Ionis' 2015 Financial Results Outperform Projections
- Ended 2015 with More Than $775M in Cash - Completed Target Enrollment in Three Phase 3 Studies for Nusinersen, IONIS-TTR(Rx) and Volanesorsen - Multiple Clinical Data Readouts Planned in 2016 from Large Pipeline of First-in-class or Best-in-class Drugs - Conference Call Webcast Thursday, February 25, 11:30 a.m. ET at www.ionispharm.com CARLSBAD, Calif., Feb. 25, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported it ended the year in a strong financial po... 
Download PDF
02/11/16Ionis Pharmaceuticals to Hold 2015 Financial Results Conference Call
- Webcast scheduled for Thursday, February 25 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb.11, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Thursday, February 25 at 11:30 a.m. Eastern Time to discuss its 2015 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be a... 
Download PDF
02/04/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 in New York, NY; Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 in Boston, MA; 28th Annual ROTH Conference on Monday, March 14, 2016 in Dana Point, CA; ... 
Download PDF
01/19/16Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced the appointment of Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C) as the company's Chief Medical Officer.  Dr. O'Dea will lead medical, clinical, and regulatory functions in support of volanesorsen and will al... 
Download PDF
01/13/16Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Ionis Earns $1.5M Milestone Payment CARLSBAD, Calif., Jan. 13, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx.  Ionis earned a $1.5 million milestone payment from GSK related to the initiation of this study.  IONIS-HBV-LRx, which was previously referred to as ISIS-GSK6-LRx, is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus (HBV).  IONIS-HBV-LRx incorporates Ionis'... 
Download PDF
01/12/16Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Ionis Earns $2.15M Milestone Payment from Biogen as Nusinersen Advances CARLSBAD, Calif., Jan. 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $2.15 million from Biogen for completing the target enrollment of the Phase 3 CHERISH study. The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA).   "Achieving our target enrollment number in CHERISH brings us ... 
Download PDF
01/11/16Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference
Significantly improved net operating loss and increased cash projected CARLSBAD, Calif., Jan. 11, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the Company expects to significantly improve upon its financial guidance for 2015.  The Company expects to end 2015 with a pro forma net operating loss (NOL) in the low $20 million range and more than $775 million in cash.  "Over the past several years, we have created a strong and consistent financial foun... 
Download PDF
01/05/16Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
First therapy designed to directly target the cause of disease CARLSBAD, Calif., Jan. 5, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). IONIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein respon... 
Download PDF
01/04/16Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.ionispharma.com. A replay will be available on the Ionis we... 
Download PDF